Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Imke Satzger; Ralf Gutzmer; Vivien Schacht; B. Völker; Martin Kerick; Bernd Timmermann; Carola Berking; Sven Klages; Lena Marks; Rudolf Herbst

doi:10.18632/oncotarget.5634

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Imke Satzger(Medizinische Hochschule Hannover), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Vivien Schacht(Harvard University), B. Völker(KRH Klinikum Nordstadt), Martin Kerick(Max Planck Institute for Molecular Genetics), Bernd Timmermann(Max Planck Institute for the Study of Societies), Carola Berking(Universitätsklinikum Erlangen), Sven Klages(Max Planck Institute for Nuclear Physics), Lena Marks(Medizinische Hochschule Hannover), Rudolf Herbst(Helios Klinikum Erfurt)

Oncotarget

October 16, 2015

10.18632/oncotarget.5634

Cited by 29

|Science|2015|3k

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2012|3k

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

|New England Journal of Medicine|2018|1.9k

The Genome of the Kinetoplastid Parasite, Leishmania major

|Science|2005|1.4k

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

|The Lancet Oncology|2018|1k

Allele frequencies of BRAF<i>V600</i> mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Related Papers